GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Inventories, Raw Materials & Components

MBCOF (Marvel Biosciences) Inventories, Raw Materials & Components : $0.00 Mil (As of Jan. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences Inventories, Raw Materials & Components?

Marvel Biosciences's inventories, raw materials & components for the quarter that ended in Jan. 2025 was $0.00 Mil.


Marvel Biosciences Inventories, Raw Materials & Components Historical Data

The historical data trend for Marvel Biosciences's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Inventories, Raw Materials & Components Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
Inventories, Raw Materials & Components
- - - - -

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Marvel Biosciences Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Marvel Biosciences Business Description

Industry
Traded in Other Exchanges
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.